The androgen receptor: A potential target for therapy of prostate cancer

Steroids

Volumn 69, Issue 2, 2004, Pages 79-85

  Santos, A F ^a   Huang, H ^a   Tindall, D J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Androgen; Androgen receptor; Hormone refractory prostate cancer; Prostate cancer; Steroid

Indexed keywords

ABARELIX; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; BICULUTAMIDE; CANCER VACCINE; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; GANCICLOVIR; GONADORELIN; HERPESVIRUS VECTOR; LEUPRORELIN; LUTEINIZING HORMONE; OMEGA 3 FATTY ACID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P21; PROTEIN P53; QUERCETIN; RAPAMYCIN; RETINOBLASTOMA PROTEIN; SULINDAC SULFONE; TESTOSTERONE; THYMIDINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENAL GLAND; ANDROGEN SYNTHESIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SCREENING; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG MECHANISM; GENE MUTATION; GENE THERAPY; HERPES SIMPLEX VIRUS VECTOR; HORMONAL THERAPY; HUMAN; HYPOPHYSIS; HYPOTHALAMUS; LEYDIG CELL; NUCLEAR MEDICINE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REVIEW; TESTIS; TUMOR SUPPRESSOR GENE; UROGENITAL SYSTEM;

ANDROGENS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 1542315629     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2003.10.005     Document Type: Review

References (85)

1. Hamalainen E., Adlercreutz H., Puska P., Pietinen P. Diet and serum sex hormones in healthy men. J. Steroid Biochem. 20:1984;459-464.
2. Dorgan J.F., Judd J.T., Longcope C., Brown C., Schatzkin A., Clevidence B.A.et al. Effects of dietary fat and fiber on plasma and urine androgens and estrogens in men: a controlled feeding study. Am. J. Clin. Nutr. 64:1996;850-855.
3. Gann P.H., Hennekens C.H., Ma J., Longcope C., Stampfer M.J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst. 88:1996;1118-1126.
4. Stanbrough M., Leav I., Kwan P.W., Bubley G.J., Balk S.P. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. Sci. USA. 98:2001;10823-10828.
5. Konety B., Nelson J. Nonandrogenic mediators of prostate growth. Hem/Onc. Clin. NA. 15(3):2001;1-16.
6. Andersson S., Berman D.M., Jenkins E.P., Russell D.W. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature. 354(6349):1991;159-161.
7. Iehle C., Radvanyi F., Gil Diez de Medina S., Ouafik L.H., Gerard H., Chopin D.et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J. Steroid Biochem. Mol. Biol. 68(5/6):1999;189-195.
8. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G.et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349(3):2003;215-224.
9. Harris K., Reese D. Treatment options in hormone-refractory prostate cancer. Drugs. 61(15):2001;2177-2192.
10. http://www.nci.nih.gov/cancerinfo/types/prostate National Cancer Institute. Cancer.gov. Hormone-refractory prostate cancer clinical trials.
11. O'Leary M.P., Roehrborn C., Andriole G., Nickel C., Boyle P., Hofner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int. 92(3):2003;262-266.
12. Isaacs J. The biology of hormone refractory prostate cancer, why does it develop? Urol. Clin. North Amer. 26(2):1999;263-273.
13. Weisser H., Ziemssen T., Krieg M. In vitro modulation of steroid 5α-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia. Steroids. 66(6):2001;521-528.
14. Brown C., Goss S., Lubahn D., Joseph D., Wilson E., Frech F.et al. Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am. J. Hum. Genet. 44:1989;264-269.
15. Koivisto P., Kolmer M., Visakorpi T., Kallioniemi O. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol. 152:1998;1-9.
16. Grossmann M., Huang H., Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J. Nat. Can. Inst. 93(22):2001;1687-1697.
17. Culig H., Kaspar F., Hobisch A., Eberle J., Reissigl A., Bartsch G. Androgen signal transduction and prostatic carcinoma. World J. Urol. 12:1994;99-103.
18. Wolf D., Herzinger T., Hermeking H., Blaschke D., Horz W. Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen. Mol. Endo. 7(7):1993;924-936.
19. Trapman J., Ris-Stalpers C., Van der Korput J., Kuiper G., Fabver P., Romijn J.et al. The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines. J. Steriod Biochem. Mol. Bio. 37(6):1990;837-842.
20. Hsiao P.W., Lin D.L., Nakao R., Chang C. The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J. Biol. Chem. 274(29):1999;20229-20234.
21. Kang H.Y., Yeh S., Fujimoto N., Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J. Biol. Chem. 274(13):1999;8570-8576.
22. Fujimoto N., Yeh S., Kang H.Y., Inui S., Chang H.C., Mizokami A.et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J. Biol. Chem. 274(12):1999;8316-8321.
23. Yeh S., Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc. Natl. Acad. Sci. USA. 93(11):1996;5517-5521.
24. Hsiao P.W., Chang C. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J. Biol. Chem. 274(32):1999;22373-22379.
25. Wang X., Yeh S., Wu G., Hsu C.L., Wang L., Chiang T.et al. Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells. J. Biol. Chem. 276(44):2001;40417-40423.
26. Aarnisalo P., Palvimo J.J., Janne O.A. REB-binding protein in androgen receptor-mediated signaling. Proc. Natl. Acad. Sci. USA. 95(5):1998;2122-2127.
27. Fu M., Wang C., Reutens A.T., Wang J., Angeletti R.H., Siconolfi-Baez L.et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J. Biol. Chem. 275(27):2000;20853-20860.
28. Debes J.D., Schmidt L.J., Huang H., Tindall D.J. P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res. 62(20):2002;5632-5636.
29. Berrevoets C.A., Doesburg P., Steketee K., Trapman J., Brinkmann A.O. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol. Endocrinol. 12(8):1998;1172-1183.
30. Ikonen T., Palvimo J.J., Janne O.A. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J. Biol. Chem. 272(47):1997;29821-29828.
31. Zhou Z.X., Kemppainen J.A., Wilson E.M. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol. Endocrinol. 9(5):1995;605-615.
32. Lin H.K., Yeh S., Kang H.Y., Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. USA. 98(13):2001;7200-7205.
33. Gioeli D., Ficarro S.B., Kwiek J.J., Aaronson D., Hancock M., Catling A.D.et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem. 277(32):2002;29304-29314.
34. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A.et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54(20):1994;5474-5478.
35. Drachenberg D.E., Elgamal A.A., Rowbotham R., Peterson M., Murphy G.P. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 41(2):1999;127-133.
36. Horvai A., Xu L., Korzus E., Brard G., Kalafus D., Mullen T.et al. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc. Natl. Acad. Sci. USA. 94:1997;1074-1079.
37. Nazareth L., Weigel N. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem. 271(33):1996;19900-19907.
38. Wang Y., Hayward S., Cao M., Thayer K., Cunha G. Cell differentiation lineage in the prostate. Differentiation. 68:2001;270-279.
39. Cunha G.R. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer. 74(Suppl. 3):1994;1030-1044.
40. Cunha GR. Growth factors as mediators of androgen action during male Urogenital development. Prostate 1996;Suppl 6:22-5.
41. Huggins C., Hodges C.V. The effect of castration. Cancer Res. 1:1941;293-297.
42. Koivisto P., Rantala I. Amplification of the androgen receptor gene is associated with p53 mutation in hormone-refractory recurrent prostate cancer. J. Pathol. 187:1999;237-241.
43. Zegarra-Moro O.L., Schmidt L.J., Huang H., Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 62(4):2002;008-13.
44. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics. CA Can. J. Clin. 52:2002;23-47.
45. Thompson I., Crawford D., deKernion J. Hormonal therapy for prostate Ca. Contemporary Urol. 13(2):2001;22-34.
46. Brawer M. The evolution of hormonal therapy for prostatic carcinoma. Rev. Urol. 3(3):2001;S1-S9.
47. Small E., Reese D. New treatment strategies in advanced prostate cancer. Rad. Clin. NA. 38(1):2000;203-211.
48. Pirtskhalaishvili G., Hrebinko R., Nelson J. The treatment of prostate cancer. An overview of options. Cancer Practice. 9(6):2001;295-316.
49. Thiele B., Weidemann W., Schnabel D., Romalo G., Schweikert H., Spindler K. Complete androgen insensitivity caused by a new frameshift deletion of two base pairs in exon 1 of the human androgen receptor gene. J. Clin. Endo Metab. 84(5):1999;1751-1753.
50. Moul J.W. Prostate specific antigen only progression of prostate cancer. J. Urol. 163(3):2000;1632-1642.
51. Djavan B., Nasu Y. Prostate cancer gene therapy - what have we learned and where are we going? Rev. Urol. 3(4):2001;179-186.
52. Wright M.E., Tsai M.J., Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol. Endocrinol. 17(9):2003;1726-1737.
53. Goldenberg D. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 43(5):2002;693-713.
54. Han M., Partin A. Current clinical applications of the 111In-capromab pendetide scan (ProstaScint Scan, Cyt-356). Rev. Urol. 3(4):2001;165-171.
55. Valone F.H., Small E., MacKenzie M., Vurch P., Lacy M., Peshwa M.V.et al. Dendritic cell-based treatment of prostate cancer: closing in on a cellular therapy. Cancer J. 7(Suppl. 2):2001;53-61.
56. McMenamin M.E., Soung P., Perera S., Kaplan I., Loda M., Sellers W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59(17):1999;4291-4296.
57. Huang H., Cheville J.C., Pan Y., Roche P.C., Schmidt L.J., Tindall D.J. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem. 276(42):2001;38830-38836.
58. Murillo H., Huang H., Schmidt L.J., Smith D.I., Tindall D.J. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology. 142(11):2001;4795-4805.
59. Graff J.R., Konicek B.W., McNulty A.M., Wang Z., Houck K., Allen S.et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 275(32):2000;24500-24505.
60. Wen Y., Hu M.C., Makino K., Spohn B., Bartholomeusz G., Yan D.H.et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60(24):2000;6841-6845.
61. Sharma M., Chuang W.W., Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J. Biol. Chem. 277(34):2002;30935-30941.
62. DiPaola R., Patel J., Rafi M. Targeting apoptosis in prostate cancer. Hem/Onc. Clin. NA. 15(3):2001;509-524.
63. Luan F., Hojo M., Maluccio M., Yamaji K., Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosupression from antitumor efficacy. Transplantation. 73(10):2002;1565-1572.
64. Neshat M., Mellinhoff I., Tran C., Thomas G., Petersen R., Frost P.et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA. 98(18):2001;10314-10319.
65. McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W., Hsieh J.T.et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Can. Res. 52:1992;6940-6944.
66. Colombel M., Symmans F., Gil S., O'Toole K.M., Chopin D., Benson M.et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143(2):1993;390-400.
67. Krajewska M., Krajewski S., Epstein J.I., Shabaik A., Sauvageot J., Song K.et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148(5):1996;1567-1576.
68. Tolcher A.W. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin. Oncol. 28(4 Suppl 15):2001;67-70.
69. Yamaguchi H., Paranawithana S., Lee M., Huang Z., Bhalla K., Wang H. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through Induction of Bax conformational change in human breast cancer cells. Cancer Res. 62:2002;466-471.
70. Xing N., Chen Y., Mitchell S., Young C. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 22(3):2001;409-414.
71. Ren F., Zhang S., Mitchell S., Butler R., Young C. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene. 19:2000;1924-1932.
72. Chung B., Mitchell S., Zhang J., Young C. Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis. 22(8):2001;1201-1206.
73. Solit D.B., Zheng F.F., Drobnjak M., Munster P.N., Higgins B., Verbel D.et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 8(5):2002;986-993.
74. Dang C., Shapiro C., Hudis C. Potential role of selective COX-2 inhibitors in cancer management. Oncology. 16(5):2002;30-36.
75. Stratton M., Alberts D. Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology. 16(5):2002;37-51.
76. Paik J.H., Ju J.H., Lee J.Y., Boudreau M.D., Hwang D.H. Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. J. Biol. Chem. 275(36):2000;28173-28179.
77. Zhu W., Smith A., Young C. A nonsteriodal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology. 140(11):1999;5451-5454.
78. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275:2000;11397-11403.
79. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K.et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 94(8):2002;585-591.
80. Andrew P., Krygier S., Djakiew D. Dihydrotestosterone (DHT) modulates the ability of NSAIDs to induce apoptosis of prostate cancer cells. Canc. Chem. Pharm. 49(3):2002;179-186.
81. Prehn R.T. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 56:1999;41-61.
82. Trachtenberg J., Gittleman M., Steidle C., Barzell W., Friedel W., Pessis D.et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J. Urol. 167(4):2002;1670-1674.
83. Ben-Josef E., Yang S., Ji T., Bidart J., Garde S., Chopa D.et al. Hormone-refractory prostate cancer cells express functional follicle- stimulating hormone receptor (FSHR). J. Urol. 161:1999;970-976.
84. Thompson I. Flare associated with LHRH-agonist therapy. Rev. Urol. 3(3):2001;S10-S14.
85. Koivisto P., Schleutker J., Helin H., Ehren-van Eekelen C., Kallioniemi O., Trapman J. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during Finasteride treatment for benign prostatic hyperplasia. Clin. Can. Res. 5:1999;3578-3582.